Abstract
Preclinical efficacy and rationale of targeting lysine280‐acetylated tau for Alzheimer’s disease therapy with ADEL‐Y01, humanized monoclonal antibody
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have